Chinese Journal of Physiology, 2019 Preeclampsia (PE) is the leading cause of maternal and fetal morbidity and mortality. It complicates around 2%–10% pregnancies worldwide due to imbalance between proangiogenic and anti-angiogenic factors, leading to incomplete placentation, ischemia, and
Zaima Ali +4 more
doaj +1 more source
Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. [PDF]
PLoS ONE, 2011 We identified that the angiotensin receptor antagonist, candesartan, has profound neurovascular protective properties when administered after ischemic stroke and was associated with a proangiogenic state at least partly explained by vascular endothelial ...
Weihua Guan +9 more
doaj +1 more source
Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia [PDF]
Journal of Histochemistry & Cytochemistry, 2002 The vascular endothelial growth factor (VEGF) family is involved in angiogenesis, and therefore VEGFs are considered as targets for anti-angiogenic therapeutic strategies against cancer. However, the physiological functions of VEGFs in quiescent tissues are unclear and may interfere with such systemic therapies.
Witmer, Antonella N. +4 more
openaire +3 more sources
Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. [PDF]
, 2008 Antihypertensive drugs are believed to lower blood pressure in pre-eclampsia by direct or central vasodilatory mechanisms. However, they could also act by decreasing production of anti-angiogenic proteins involved in the pathophysiology of hypertension ...
Muttukrishna Shanthi +11 more
core +1 more source
Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy [PDF]
, 2007 Maternal endothelial dysfunction in preeclampsia is associated with increased soluble fms-like tyrosine kinase-1 (sFlt-1), a circulating antagonist of vascular endothelial growth factor and placental growth factor.
Kellems, Rodney E. +19 more
core +1 more source
Modulation of Angiogenesis by a Tetrameric Tripeptide That Antagonizes Vascular Endothelial Growth Factor Receptor 1 [PDF]
Journal of Biological Chemistry, 2008 Vascular endothelial growth factor receptor-1 (VEGFR-1, also known as Flt-1) is involved in complex biological processes often associated to severe pathological conditions like cancer, inflammation, and metastasis formation. Consequently, the search for antagonists of Flt-1 has recently gained a growing interest.
Ponticelli S +10 more
openaire +5 more sources
The functions and applications of A7R in anti-angiogenic therapy, imaging and drug delivery systems
Asian Journal of Pharmaceutical Sciences, 2019 Vascular endothelial growth factor receptor 2 (VEGFR-2) and neuropilin-1 (NRP-1) are two prominent antiangiogenic targets. They are highly expressed on vascular endothelial cells and some tumor cells.
Lu Lu +4 more
doaj +1 more source
针刺研究, 2021 Objective To observe the effect of moxibustion on the growth of tumor and expression of fibroblast growth factor receptor 1(FGFR1) and vascular endothelial cell growth factor receptor 2(VEGFR2) in mice with sarcoma, so as to explore its mechanisms ...
LI Li-jun +3 more
doaj
Platelets, 2022 CIGB-247 is a vascular endothelial growth factor (VEGF)-based active immunotherapy and it is currently under investigation for cancer treatment. This specific active immunotherapy encompasses two vaccine candidates that use a human VEGF variant molecule ...
Javier Sánchez Ramírez +3 more
doaj +1 more source
Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages [PDF]
, 2007 Genetic depletion of macrophages in Polyoma Middle T oncoprotein (PyMT)-induced mammary tumors in mice delayed the angiogenic switch and the progression to malignancy.
Pollard, Jeffrey W +7 more
core +1 more source